Tissue and organ transplantation involves surgically removing an organ or tissue from one person (the organ donor) and placing it into another person (the recipient) who needs the body part. The organs and tissues that are commonly transplanted include kidney, liver, heart, lungs, pancreas, intestine, skin and corneas. The increasing cases of chronic illnesses such as cardiovascular diseases, cancer, kidney failures is fueling the demand for organ transplantation procedures.
The global Tissue And Organ Transplantation Market is estimated to be valued at Us$ 20.8 Bn in 2024 and is expected to exhibit a CAGR Of 7.9% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Growing prevalence of chronic diseases and the lack of donated organs are expected to drive the growth of the tissue and organ transplantation market over the forecast period. Chronic illnesses like cardiovascular disease, cancer, kidney failures and liver diseases are on the rise. According to American Heart Association, cardiovascular diseases account for 17.9 million deaths globally every year. The rising cases of such chronic diseases has increased the demand for organ transplantation procedures. However, the market is constrained by challenges like shortage of organ donors and high costs associated with transplantation procedures. According to WHO, every day 8000 people enlist their names on transplant waiting lists while only 9378 organ transplantations are performed globally. This huge gap between demand and supply is expected to drive health organizations and medical institutes to focus on transplanting artificial organs.
SWOT Analysis
Strength: The tissue and organ transplantation market provides lifesaving surgeries to patients in need. There is growing awareness about organ donation which is helping increase the donor pool. Research to develop artificial organs and tissues is reducing the demand-supply gap.
Weakness: There is a severe shortage of organ donors globally. Cultural and religious beliefs prevent some people from donation. Immunosuppressant drugs needed after transplantation have side effects. Rejection of transplanted organs remains a challenge.
Opportunity: The aging population and rise in lifestyle diseases driving transplant procedures. Stem cell therapies and 3D bioprinting of tissues/organs offer new opportunities. Advances in immunology may reduce need for lifelong anti-rejection drugs. Government initiatives are promoting organ donation in some countries.
Threats: Infrastructure gaps exist in developing nations for transplantation. Legal and ethical issues surround new tissue engineering methods. Organ trafficking and transplantation tourism remain problems in some areas. Future pandemics can impact donor availability.
Key Takeaways
The Global Tissue And Organ Transplantation Market Demand is expected to witness high growth. The market size is forecast to reach US$ 20.8 billion by 2024, growing at a CAGR of 7.9% during the forecast period.
North America currently dominates due to high transplantation rates, technological advancements, and supportive insurance policies in countries like the US and Canada. However, Asia Pacific is poised to be the fastest growing region thanks to growing healthcare investment, rising medical tourism, and an aging population in China, India and other developing nations.
Regional analysis :
Key players operating in the tissue and organ transplantation market include Probi AB, Chr. Hansen Holding A/S, Danone S.A., Yakult Honsha Co., Ltd., Nestle S.A., DowDuPont Inc., Kerry Group plc, BioGaia AB, Probiotics International Limited (Protexin), UAS Laboratories LLC. Probi AB and Chr. Hansen are among the largest players focusing on microbiome-based solutions to reduce immunosuppressant drug dependency after transplantation after transplantation.
Get more insights on this topic :
Check more trending articles on this topic:
Greek
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)